These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38568956)

  • 1. Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
    Podany AT; Cramer Y; Imperial M; Rosenkranz SL; Avihingsanon A; Arduino R; Samaneka W; Gelmanova I; Savic R; Swindells S; Dawson R; Luetkemeyer AF
    Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38568956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
    Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
    Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
    Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
    J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
    Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
    Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
    Radtke KK; Ernest JP; Zhang N; Ammerman NC; Nuermberger E; Belknap R; Boyd R; Sterling TR; Savic RM
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0170521. PubMed ID: 34606336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated management of cryptococcal meningitis and concurrent opportunistic infections to improve outcomes in advanced HIV disease: a randomised strategy trial.
    Ellis J; Nsangi L; Bangdiwala A; Hale G; Gakuru J; Kagimu E; Mugabi T; Kigozi E; Tukundane A; Okirwoth M; Kandole TK; Cresswel F; Harrison TS; Moore D; Fielding K; Meya D; Boulware D; Jarvis JN
    Wellcome Open Res; 2024; 9():14. PubMed ID: 38854693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
    Malik AA; Farooq S; Jaswal M; Khan H; Nasir K; Fareed U; Shahbaz S; Amanullah F; Safdar N; Khan AJ; Keshavjee S; Becerra MC; Hussain H
    Lancet Child Adolesc Health; 2021 May; 5(5):350-356. PubMed ID: 33770510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Jul; ():. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda.
    Musinguzi A; Aschmann HE; Kadota JL; Nakimuli J; Welishe F; Kakeeto J; Namale C; Akello L; Nakitende A; Berger C; Katamba A; Tumuhamye J; Kiwanuka N; Dowdy DW; Cattamanchi A; Semitala FC
    IJTLD Open; 2024 Feb; 1(2):83-89. PubMed ID: 38966690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
    Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
    Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
    Podany AT; Leon-Cruz J; Hakim J; Supparatpinyo K; Omoz-Oarhe A; Langat D; Mwelase N; Kanyama C; Gupta A; Benson CA; Chaisson RE; Swindells S; Fletcher CV;
    J Antimicrob Chemother; 2021 Feb; 76(3):718-721. PubMed ID: 33241266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment.
    Taylor A; Winthrop E; Pecora Fulco P
    Int J STD AIDS; 2023 Dec; 34(14):1075-1077. PubMed ID: 37702618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
    Jarrett RT; van der Heijden Y; Shotwell MS; Chihota V; Marzinke MA; Chaisson RE; Dooley KE; Churchyard GJ
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0129722. PubMed ID: 36622148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
    Griesel R; Zhao Y; Simmons B; Omar Z; Wiesner L; Keene CM; Hill AM; Meintjes G; Maartens G
    Lancet HIV; 2023 Jul; 10(7):e433-e441. PubMed ID: 37230101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.